Clinical Trial

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 18, 2024 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This multicentric randomized trial will compare the efficacy and safety of neoadjuvant chemotherapy + surgery + adjuvant chemotherapy or surgery + adjuvant chemotherapy in patients with high-risk resectable pancreatic cancer. NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) will be used as the chemotherapy regimen.
Trial Details
NCT Number NCT06210360
Lead Sponsor Changhai Hospital
Conditions Pancreatic Cancer
Enrollment 134 participants
Start Date 2024-02-01
Primary Completion 2025-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-01-18